TONAWANDA, N.Y. — Martin Kober is convinced the painting of a dying Jesus that hung above the mantel in his upstate New York childhood home is the work of Michelangelo. Getting experts to agree remains the $300 million hurdle. That’s the potential value of the 19-by-25-inch work that Kober’s family affectionately calls the “the Mike,”...
NYS Entity Status
NYS Filing Date
SEPTEMBER 18, 2013
NYS DOS ID#
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - DAVID MARTINEZ PAINTING CORP.
AROUND THE WEB
- Man convinced living room painting is $300M Michelangelo masterpiece
By Associated Press - Thursday Jul 20, 2017
- Christopher Columbus Statue in Central Park Is Vandalized
By SARAH MASLIN NIR and JEFFERY C. MAYS - Tuesday Sep 12, 2017
An 1892 bronze statue of Columbus was found covered with graffiti, its hands painted red.
- Sunday Routine: How Paul Rabil, Lacrosse Player, Spends His Sundays
By ANDREW COTTO - Friday Jul 28, 2017
The athlete, entrepreneur and Williamsburg, Brooklyn, resident spends a lot of time by himself, reading, writing, working, and sometimes even painting.
- Rare painting stolen in museum heist found in antique store
By Ruth Brown - Saturday Aug 12, 2017
A masterpiece by painter Willem de Kooning that was stolen in a famous museum heist three decades ago has finally been found — at an antique store 200 miles away. The store’s owner, David Van Auker, unwittingly picked up “Woman-Ochre” in an estate sale on Aug. 1 but had no idea he’d found a $160...
- Yankees’ Nolan Martinez Ready To Put Injuries Behind Him
By Josh Norris - Tuesday Aug 15, 2017
New York's 2016 third-rounder has dealt with shoulder issues this year.
The post Yankees’ Nolan Martinez Ready To Put Injuries Behind Him appeared first on BaseballAmerica.com.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]